Cysteine proteases and cysteine protease inhibitors in non-small cell lung cancer - PubMed (original) (raw)
Affiliations
- PMID: 9921922
Cysteine proteases and cysteine protease inhibitors in non-small cell lung cancer
E Krepela et al. Neoplasma. 1998.
Abstract
In this study we investigated the levels of two lysosomal cysteine protease proteins cathepsin B (CB) and cathepsin L (CL) and the levels of three cysteine protease inhibitor proteins stefin A (SFA), stefin B (SFB) and cystatin C (CNC) in squamous-cell lung carcinoma (SQCLC) and matched lung parenchyma specimens and examined the inhibition of CB and cathepsin C (CC) activities by endogenous inhibitors in extracts from SQCLC, lung adenocarcinoma (LAC) and lung parenchyma specimens. We found that Stage I SQCLCs contained significantly increased levels of CB protein, CB activity and SFA protein as compared to matched lungs. Neither the levels of CL protein nor the levels of SFB protein nor the levels of CNC protein in Stage I SQCLCs and the lungs were significantly different, but the levels of CB and CL proteins as well as the levels of SFA and SFB proteins showed significant positive correlation in SQCLCs. In SQCLCs as well as in the lungs the level of SFB protein was significantly higher than the level of SFA protein or the level of CNC protein. In the lungs the levels of SFA protein and CNC protein revealed a weak negative correlation trend. In extracts from SQCLCs the level of SFA protein showed a weak negative correlation with the residual CB activity (i.e. the activity remaining after extract preincubation) whereas in extracts from the lungs the level of CNC protein displayed a weak negative correlation trend with the residual CB activity and with the residual CC activity. We observed that SQCLCs and LACs contained not only a significantly increased activity of CB but also a significantly higher inhibitory potential against the activity of endogenous CB as compared to matched lungs. Leupeptin, a small inhibitor of CB, was capable to protect CB in lung carcinoma and lung parenchyma extracts from preincubation-induced inhibition, revealing an active-site directed and competitive nature of CB inhibition by endogenous cystatins. Ultrafiltration passaged protein preparations of nominal Mr < or = 30,000 obtained from extracts of SQCLCs inhibited significantly higher quantities of activity of purified bovine spleen CC than did such protein preparations from matched lungs. Reaction courses of purified bovine spleen CC that had been preincubated with such protein preparations resembled those of endogenous CC from SQCLC and lung extracts showing a slow steady-state approach. These observations and the relaxation kinetics of CC from SQCLC and lung extracts suggest that CC in the extracts may be complexed with some cystatins. In conclusion, our results indicate that quantitatively different combinations of cystatins are the major constituents of the inhibitory potential against CB and CC in SQCLCs and the lungs.
Similar articles
- Cathepsin B, thiols and cysteine protease inhibitors in squamous-cell lung cancer.
Krepela E, Procházka J, Kárová B, Cermák J, Roubková H. Krepela E, et al. Neoplasma. 1997;44(4):219-39. Neoplasma. 1997. PMID: 9473776 - Lysosomal dipeptidyl-peptidases I and II in human squamous cell lung carcinoma and lung parenchyma.
Krepela E, Procházka J, Mynaríková H, Kárová B, Cermák J, Roubková H. Krepela E, et al. Neoplasma. 1996;43(3):171-8. Neoplasma. 1996. PMID: 8841504 - Human recombinant pro-dipeptidyl peptidase I (cathepsin C) can be activated by cathepsins L and S but not by autocatalytic processing.
Dahl SW, Halkier T, Lauritzen C, Dolenc I, Pedersen J, Turk V, Turk B. Dahl SW, et al. Biochemistry. 2001 Feb 13;40(6):1671-8. doi: 10.1021/bi001693z. Biochemistry. 2001. PMID: 11327826 - Cysteine proteinases and their endogenous inhibitors: target proteins for prognosis, diagnosis and therapy in cancer (review).
Kos J, Lah TT. Kos J, et al. Oncol Rep. 1998 Nov-Dec;5(6):1349-61. doi: 10.3892/or.5.6.1349. Oncol Rep. 1998. PMID: 9769367 Review. - Cathepsin B and its endogenous inhibitors: the role in tumor malignancy.
Sloane BF, Moin K, Krepela E, Rozhin J. Sloane BF, et al. Cancer Metastasis Rev. 1990 Dec;9(4):333-52. doi: 10.1007/BF00049523. Cancer Metastasis Rev. 1990. PMID: 2097084 Review.
Cited by
- Gene expression in rats with Barrett's esophagus and esophageal adenocarcinoma induced by gastroduodenoesophageal reflux.
Cheng P, Gong J, Wang T, Chen J, Liu GS, Zhang R. Cheng P, et al. World J Gastroenterol. 2005 Sep 7;11(33):5117-22. doi: 10.3748/wjg.v11.i33.5117. World J Gastroenterol. 2005. PMID: 16127739 Free PMC article. - Detection of cathepsin B, cathepsin L, cystatin C, urokinase plasminogen activator and urokinase plasminogen activator receptor in the sera of lung cancer patients.
Chen Q, Fei J, Wu L, Jiang Z, Wu Y, Zheng Y, Lu G. Chen Q, et al. Oncol Lett. 2011 Jul;2(4):693-699. doi: 10.3892/ol.2011.302. Epub 2011 May 11. Oncol Lett. 2011. PMID: 22848251 Free PMC article. - Cystatin C deficiency promotes epidermal dysplasia in K14-HPV16 transgenic mice.
Yu W, Liu J, Shi MA, Wang J, Xiang M, Kitamoto S, Wang B, Sukhova GK, Murphy GF, Orasanu G, Grubb A, Shi GP. Yu W, et al. PLoS One. 2010 Nov 15;5(11):e13973. doi: 10.1371/journal.pone.0013973. PLoS One. 2010. PMID: 21085595 Free PMC article. - Cysteine proteinase inhibitor cystatin C in squamous cell carcinoma of the head and neck: relation to prognosis.
Strojan P, Oblak I, Svetic B, Smid L, Kos J. Strojan P, et al. Br J Cancer. 2004 May 17;90(10):1961-8. doi: 10.1038/sj.bjc.6601830. Br J Cancer. 2004. PMID: 15138478 Free PMC article. - Serum cystatin C and emphysema: results from the National Health and Nutrition Examination Survey (NHANES).
Rokadia HK, Agarwal S. Rokadia HK, et al. Lung. 2012 Jun;190(3):283-90. doi: 10.1007/s00408-012-9374-z. Lung. 2012. PMID: 22286538
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials
Miscellaneous